Company intelligence / Profile preview
SapiensBio
Seongnam, South Koreasapiensbio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
SapiensBio has developed an integrated AI/wet-lab drug discovery platform called Sapientia. Their lead program, SBC101, is in pre-clinical development targeting severe diseases with unmet medical need. The company leverages single-cell RNA sequencing and organoid models to accelerate target validation and candidate selection.
- Therapeutic areas
- OtherNeurology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Joint R&D agreement with ADDI in the UKSelected operating company for Korea's Third National New Drug Development Project
Beyond the preview
Go deeper on SapiensBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SapiensBio.